GLP1R and obesity due to melanocortin 4 receptor deficiency: More recently the clinical use of GLP-1R agonist based therapeutics at high doses for the treatment of obesity and diabetes has resulted in weight loss in the 9–16% range over 26–68 weeks depending on diabetes status and the degree of lifestyle intervention7,8.